tradingkey.logo

Kamada Ltd

KMDA
View Detailed Chart
8.210USD
+0.190+2.37%
Close 02/06, 16:00ETQuotes delayed by 15 min
473.56MMarket Cap
23.35P/E TTM

Kamada Ltd

8.210
+0.190+2.37%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.37%

5 Days

-1.32%

1 Month

+10.50%

6 Months

+17.12%

Year to Date

+16.29%

1 Year

+18.81%

View Detailed Chart

TradingKey Stock Score of Kamada Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Kamada Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kamada Ltd's Score

Industry at a Glance

Industry Ranking
51 / 159
Overall Ranking
151 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Kamada Ltd Highlights

StrengthsRisks
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.44% year-on-year.
Fairly Valued
The company’s latest PE is 23.35, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.82M shares, decreasing 3.69% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 3.20K shares of this stock.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
13.000
Target Price
+62.09%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kamada Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Kamada Ltd Info

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Ticker SymbolKMDA
CompanyKamada Ltd
CEOLondon (Amir)
Websitehttps://www.kamada.com/
KeyAI